The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer
| Autor: | Raymond N DuBois, Colin G. Crosby |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Colorectal cancer Pharmacology Bioinformatics Drug Delivery Systems Neoplasms Epidemiology medicine Animals Humans Cyclooxygenase Inhibitors Pharmacology (medical) Rofecoxib Cancer prevention Cyclooxygenase 2 Inhibitors biology business.industry Membrane Proteins Cancer Chronic ingestion medicine.disease Isoenzymes Cyclooxygenase 2 Prostaglandin-Endoperoxide Synthases Celecoxib biology.protein Cyclooxygenase business Signal Transduction medicine.drug |
| Zdroj: | Expert Opinion on Emerging Drugs. 8:1-7 |
| ISSN: | 1744-7623 1472-8214 |
| DOI: | 10.1517/14728214.8.1.1 |
| Popis: | Cyclooxygenase (COX)-2, an inducible enzyme involved in prostaglandin biosynthesis, has attracted considerable attention recently, due to its role in human cancer biology. Several studies have correlated an increase in the expression of COX-2 with a poor clinical outcome, while epidemiological studies demonstrate a reduced risk of cancer mortality in persons with longterm, chronic ingestion of non-steroidal anti-inflammatory drugs (NSAIDs). Originally, these observations were made in patients with colorectal cancer, and subsequent studies suggest a protective role of NSAIDs in other human cancers as well. With the development of COX-2 specific inhibitors, numerous laboratory and clinical studies are underway to help understand the role of COX-2 in cancer and the potential use of COX-2 selective inhibitors for cancer treatment or prevention. This review focuses on the physiological function of COX, and the clinical rationale for evaluating COX-2 selective inhibitors for use in oncology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|